Seres Therapeutics Inc. (NASDAQ:MCRB) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
Several other brokerages have also recently commented on MCRB. Cowen and Company reaffirmed a “buy” rating on shares of Seres Therapeutics in a research report on Friday, July 29th. HC Wainwright started coverage on Seres Therapeutics in a research report on Friday, July 29th. They issued a “buy” rating and a $50.00 target price for the company. FBR & Co dropped their price objective on Seres Therapeutics from $43.00 to $23.00 and set an “outperform” rating for the company in a research note on Friday, August 12th. Canaccord Genuity reiterated a “buy” rating and set a $20.00 price objective on shares of Seres Therapeutics in a research note on Monday, August 1st. Finally, Bank of America Corp. lowered Seres Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, August 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $31.57.
Shares of Seres Therapeutics (NASDAQ:MCRB) opened at 11.44 on Wednesday. The firm’s market cap is $460.73 million. Seres Therapeutics has a 12-month low of $8.05 and a 12-month high of $44.51. The company has a 50-day moving average of $11.81 and a 200 day moving average of $22.74.
Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Thursday, August 11th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.24. The company earned $3 million during the quarter, compared to analysts’ expectations of $4.20 million. Seres Therapeutics’s revenue for the quarter was up NaN% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.45) earnings per share. Equities analysts predict that Seres Therapeutics will post ($2.33) EPS for the current year.
In related news, insider Michele Trucksis sold 38,064 shares of the company’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $35.14, for a total transaction of $1,337,568.96. Following the completion of the sale, the insider now directly owns 38,064 shares in the company, valued at approximately $1,337,568.96. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider John G. Aunins sold 9,390 shares of the company’s stock in a transaction on Monday, August 29th. The stock was sold at an average price of $10.87, for a total value of $102,069.30. Following the sale, the insider now owns 192,125 shares of the company’s stock, valued at $2,088,398.75. The disclosure for this sale can be found here. Insiders own 41.90% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Birchview Capital LP acquired a new stake in shares of Seres Therapeutics during the second quarter valued at $145,000. Pacad Investment Ltd. acquired a new stake in shares of Seres Therapeutics during the second quarter valued at $198,000. First Mercantile Trust Co. acquired a new stake in shares of Seres Therapeutics during the second quarter valued at $229,000. Fox Run Management L.L.C. acquired a new stake in shares of Seres Therapeutics during the third quarter valued at $257,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Seres Therapeutics during the second quarter valued at $273,000. Institutional investors and hedge funds own 78.28% of the company’s stock.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.